293 related articles for article (PubMed ID: 26463529)
21. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
22. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Nakamura N; Hara T; Shibata Y; Matsumoto T; Nakamura H; Ninomiya S; Kito Y; Kitagawa J; Kanemura N; Goto N; Shiraki M; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
24. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
[No Abstract] [Full Text] [Related]
25. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
27. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
28. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
29. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
30. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
[TBL] [Abstract][Full Text] [Related]
31. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Zhang WH; Li GY; Ma YJ; Li ZC; Zhu Y; Chang J; Hao SG; Tao R
Ann Hematol; 2018 Oct; 97(10):1809-1816. PubMed ID: 29754271
[TBL] [Abstract][Full Text] [Related]
32. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
33. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
34. Transient adrenal insufficiency in diffuse large B cell lymphoma patients after chemotherapy with short-course, high-dose corticosteroids.
Owattanapanich W; Sirinvaravong S; Suphadirekkul K; Wannachalee T
Ann Hematol; 2018 Dec; 97(12):2403-2410. PubMed ID: 30109424
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
Kikukawa M; Miyazaki K; Kiuchi A; Abe S; Fujii H; Kanaya K; Shin K; Iwamoto T
Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
[TBL] [Abstract][Full Text] [Related]
36. Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
Eyre TA; Salisbury R; Eyre DW; Watson C; Collins GP; Hatton CS
Br J Haematol; 2016 May; 173(3):487-91. PubMed ID: 26223361
[No Abstract] [Full Text] [Related]
37. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
38. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
39. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
